Page 247 - Drug Class Review

Drug Effectiveness Review Project

Drugs Authors: Wilkinson et al. 29 Country: Multinational (UK, South Africa, Switzerland) Eisai, Inc. and Pfizer, Inc. To compare the tolerability and cognitive effects of DON vs. RIV in patients with mild to moderate AD Study design: RCT (open label) Setting: Multi-center (19) rivastigmine donepezil 6-12 mg/d (flexible) 5-10 mg/d (flexible) 12 weeks 12 weeks 55 56 Patients > 50 yrs; probable or possible AD according to DSM-IV and NINCDS; MMSE score of 10-26; CT or MRI scan within past 12 months consistent with diagnosis of AD; available caregiver History of DON or RI

Alzheimer Year: 2002 Sample size: 111

Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs